Drug Trial Radar · NCT01959529
A Trial Comparing Cardiovascular Safety of Insulin Degludec Versus Insulin Glargine in Subjects With Type 2 Diabetes at High Risk of Cardiovascular Events
Last checked: Nov 20, 2026Latest source record: Jul 24, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
7,637
Actual
Start
Oct 29, 2013
Primary completion
Oct 16, 2016
Study completion Oct 16, 2016
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Oct 10, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial is conducted globally. The aim of this trial is to compare cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events.
Conditions
- Diabetes
- Diabetes Mellitus, Type 2
Interventions
insulin degludecDrug
Injected once daily subcutaneously (s.c., under the skin)
insulin glargineDrug
Injected once daily subcutaneously (s.c., under the skin)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Randomisation to First Occurrence of a Major Adverse Cardiovascular Event (MACE): Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal StrokeTime frame: From randomisation to individual end of trial date (maximum patient year observation: 2.75 years)
Locations
446 sites in 20 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Birmingham, Alabama
Novo Nordisk Investigational Site
Montgomery, Alabama
Novo Nordisk Investigational Site
Montgomery, Alabama
Novo Nordisk Investigational Site
Gilbert, Arizona
Novo Nordisk Investigational Site
Glendale, Arizona
Novo Nordisk Investigational Site
Litchfield Park, Arizona
Novo Nordisk Investigational Site
Phoenix, Arizona
Novo Nordisk Investigational Site
Tucson, Arizona
Novo Nordisk Investigational Site
Tucson, Arizona
Novo Nordisk Investigational Site
Tucson, Arizona
Novo Nordisk Investigational Site
Little Rock, Arkansas
Novo Nordisk Investigational Site
Little Rock, Arkansas
Novo Nordisk Investigational Site
Searcy, Arkansas
Novo Nordisk Investigational Site
Chula Vista, California
Novo Nordisk Investigational Site
Concord, California
Novo Nordisk Investigational Site
Downey, California
Novo Nordisk Investigational Site
Duarte, California
Novo Nordisk Investigational Site
Encino, California
Novo Nordisk Investigational Site
Fresno, California
Novo Nordisk Investigational Site
Greenbrae, California
Novo Nordisk Investigational Site
Huntington Beach, California
Novo Nordisk Investigational Site
Inglewood, California
Novo Nordisk Investigational Site
La Jolla, California
Novo Nordisk Investigational Site
La Mesa, California
Novo Nordisk Investigational Site
Lancaster, California
Novo Nordisk Investigational Site
Long Beach, California
Novo Nordisk Investigational Site
Los Alamitos, California
Novo Nordisk Investigational Site
Mission Hills, California
Novo Nordisk Investigational Site
Montclair, California
Novo Nordisk Investigational Site
Monterey, California
Novo Nordisk Investigational Site
North Hollywood, California
Novo Nordisk Investigational Site
Palm Springs, California
Novo Nordisk Investigational Site
Poway, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Diego, California
Novo Nordisk Investigational Site
San Ramon, California
Novo Nordisk Investigational Site
Santa Ana, California
Novo Nordisk Investigational Site
Sherman Oaks, California
Novo Nordisk Investigational Site
Thousand Oaks, California
Showing 40 of 446 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.